Multiple Sclerosis (MS) Drug Market

RECENT NEWS
New York Times  Aug 21  Comment 
The experimental drug ofatumumab would bolster the Swiss pharmaceutical company’s portfolio of multiple sclerosis treatments.
Forbes  Aug 12  Comment 
Children with multiple sclerosis (MS) who engage in regular exercise may potentially have a milder form of their disease with fewer symptoms, according to results of a new study published online today in the Journal, Neurology.
Forbes  Aug 4  Comment 
And why would it be so hard for someone like her to do that today?
guardian.co.uk  Jul 28  Comment 
Beach wheelchairs could help disabled people like me access British beaches and make a splash while on holiday, so why don’t we have more of them? I’m a big fan of beach holidays, and although in a wheelchair with primary progressive multiple...
MedPage Today  Jul 21  Comment 
(MedPage Today) -- Location in cerebral cortex, more than global white matter lesion volume, tied to disability.
TheStreet.com  Jul 2  Comment 
NEW YORK (TheStreet) -- Shares of Receptos were falling 1.5% to $193.42 in midday training Tuesday. The biotech company is currently working on a drug which may help combat several diseases such as multiple sclerosis and Crohn's disease, among...
newratings.com  Jun 30  Comment 
SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY.PK), announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif),...
New York Times  Jun 18  Comment 
A federal appeals court on Thursday again invalidated a patent protecting Teva Pharmaceutical’s big-selling drug, Copaxone, which can cost $60,000 a year.
Benzinga  Jun 9  Comment 
RedHill Biopharma Ltd. (Nasdaq: RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal...
Benzinga  May 29  Comment 
Alkermes plc (NASDAQ: ALKS) today announced that data from its phase 1, randomized, double-blind clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS), is scheduled to...




 
TOP CONTRIBUTORS

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki